Keywords: 1st-qtr, sales, dip, novartis, switzerland, health, care
1st-qtr 1999 sales dip for Novartis
Article | 21 April 1999
Switzerland's health care giant Novartis reported a 1% decline infirst-quarter 1999 sales at 7.87 billion Swiss francs ($5.34 billion), though at local-currency level this ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
